Death receptors: Targets for cancer therapy

Experimental Cell Research

Volumn 316, Issue 6, 2010, Pages 887-899

  Mahmood, Zafar ^a   Shukla, Yogeshwer ^a  

^a CSIR INDIAN INSTITUTE OF TOXICOLOGY RESEARCH   (India)

Author keywords

Death receptors; Ectodysplasin A receptor; Nerve growth factor receptor; TNF related apoptosis inducing ligand; Tumor necrosis factor

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; BLEOMYCIN; BORTEZOMIB; CARBOPLATIN; CISPLATIN; DEATH RECEPTOR; DEATH RECEPTOR 3; DEATH RECEPTOR 4; DEATH RECEPTOR 5; DEATH RECEPTOR 6; DOXORUBICIN; EDAR RECEPTOR; ETOPOSIDE; FAS ANTIGEN; FLICE INHIBITORY PROTEIN; FLUOROURACIL; GEMCITABINE; MITOMYCIN C; MONOCLONAL ANTIBODY; NERVE GROWTH FACTOR RECEPTOR; PACLITAXEL; PROCASPASE 8; PROTEIN P53; TUMOR NECROSIS FACTOR RECEPTOR; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR STIMULATING AGENT; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

APOPTOSIS; CANCER CELL; CANCER CELL CULTURE; CELL DEATH; CELL TRANSFORMATION; CLINICAL TRIAL; COLORECTAL CANCER; CYTOTOXICITY; DRUG TARGETING; ENZYME ACTIVATION; GROWTH REGULATION; HOMEOSTASIS; HUMAN; LUNG NON SMALL CELL CANCER; MALIGNANT NEOPLASTIC DISEASE; NONHODGKIN LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN FAMILY; REVIEW; SIGNAL TRANSDUCTION; SOLID TUMOR;

EID: 77649181792     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2009.12.011     Document Type: Review

References (113)

1. Bhardwaj A., and Aggarwal B.B. Receptor-mediated choreography of life and death. J. Clin. Immunol. 23 (2003) 317-332
2. Ashkenazi A., and Dixit V.M. Death receptors: signaling and modulation. Sciences 281 (1998) 1305-1308
3. Osborne B.A. Apoptosis and the maintenance of homoeostasis in the immune system. Curr. Opin. Immunol. 8 (1996) 245-254
4. Naismith J.H., and Sprang S.R. Modularity in the TNF-receptor family. Trends Biochem. Sci. 23 (1998) 74-79
5. Fulda S., and Debatin K.M. Exploiting death receptor signaling pathways for tumor therapy. Biochim. Biophys. Acta 1705 (2004) 27-41
6. Singh A., Ni J., and Aggarwal B.B. Death domain receptors and their role in cell demise. J. Interferon Cytokine Res. 18 (1998) 439-450
7. walczak H., and Krammer P.H. The CD95 (APO-1/Fas) and the TRAIL (APO-2L) apoptosis systems. Exp. Cell Res. 256 (2000) 58-66
8. Wang S., and El-Deiry W.S. TRAIL and apoptosis induction by TNF-family DRs. Oncogene 22 (2003) 8628-8633
9. Emery J.G., McDonnell P., Burke M.B., Deen K.C., Lyn S., Silverman C., Dul E., Appelbaum E.R., Eichman C., DiPrinzio R., Dodds R.A., James I.E., Rosenberg M., Lee J.C., and Young P.R. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J. Biol. Chem. 273 (1998) 14363-14367
10. French L.E., and Tschopp J. Protein based therapeutic approaches targeting death receptors. Cell Death Differ. 10 (2003) 117-123
11. Wajant H. Death receptors. Essays Biochem. 39 (2003) 53-71
12. Wajant H., Pfizenmaier K., and Scheurich P. TNF-related apoptosis-inducing ligand (TRAIL) and its receptors in tumor surveillance and cancer therapy. Apoptosis 5 (2002) 449-459
13. Papenfuss K., Cordier S.M., and Walczak H. Death receptors as targets for anti-cancer therapy. J. Cell. Mol. Med. 12 (2008) 2566-2585
14. de Jong S., Timmer T., Heijenbrok F.J., and de Vries E.G. Death receptor ligands, in particular TRAIL, to overcome drug resistance. Cancer Metastasis Rev. 20 (2001) 51-56
15. Trauth B.C., Klas C., Peters A.M., Matzku S., Möller P., Falk W., Debatin K.M., and Krammer P.H. Monoclonal antibody-mediated tumor regression by induction of apoptosis. Science 245 (1989) 301-305
16. Takahashi T., Tanaka M., Brannan C.I., Jenkins N.A., Copeland N.G., Suda T., and Nagata S. Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand. Cell 76 (1994) 969-976
17. Krammer P.H. CD95′s deadly mission in the immune system. Nature 407 (2000) 789-795
18. Locksley R.M., Killeen N., and Lenardo M.J. The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell 104 (2001) 487-501
19. Kitson J., Raven T., Jiang Y.P., Goeddel D.V., Giles K.M., Pun K.T., Grinham C.J., Brown R., and Farrow S.N. A death-domain-containing receptor that mediates apoptosis. Nature 384 (1996) 372-375
20. Chinnaiyan A.M., O'Rourke K., Yu G.L., Lyons R.H., Garg M., Duan D.R., Xing L., Gentz R., Ni J., and Dixit V.M. Signal transduction by DR3, a death domain-containing receptor related to TNFR-1 and CD95. Science 274 (1996) 990-992
21. Marsters S.A., Sheridan J.P., Donahue C.J., Pitti R.M., Gray C.L., Goddard A.D., Bauer K.D., and Ashkenazi A. Apo-3, a new member of the tumor necrosis factor receptor family, contains a death domain and activates apoptosis and NF-κB. Curr. Biol. 6 (1996) 1669-1676
22. Migone T.S., Zhang J., Luo X., Zhuang L., Chen C., Hu B., Hong J.S., Perry J.W., Chen S.F., Zhou J.X., Cho Y.H., Ullrich S., Kanakaraj P., Carrell J., Boyd E., Olsen H.S., Hu G., Pukac L., Liu D., Ni J., Kim S., Gentz R., Feng P., Moore P.A., Ruben S.M., and Wei P. TL1A is a TNF-like ligand for DR3 and TR6/DcR3 and function as a T-cell costimulator. Immunity 16 (2002) 479-492
23. Wang E.C., Thern A., Denzel A., Kitson J., Farrow S.N., and Owen M.J. DR3 regulates negative selection during thymocyte development. Mol. Cell. Biol. 21 (2001) 3451-3461
24. Pitti R.M., Marsters S.A., Ruppert S., Donahue C.J., Moore A., and Ashkenazi A. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor family. J. Biol. Chem. 271 (1996) 12687-12690
25. Wiley S.R., Schooley K., Smolak P.J., Din W.S., Huang C.P., Nicholl J.K., Sutherland G.R., Davis-Smith T., Rauch C., Smith C.A., and Goodwin R.G. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 3 (1995) 673-682
26. MacFarlane M. TRAIL-induced signaling and apoptosis. Toxicol. Lett. 139 (2003) 89-97
27. Wu G.S., Burns T.F., Zhan Y., Alnemri E.S., and El-Deiry W.S. Molecular cloning and functional analysis of the mouse homologue of the KILLER/DR5 tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) death receptor. Cancer Res. 59 (1999) 2770-2775
28. Finnberg N., Gruber J.J., Fei P., Rudolph D., Bric A., Kim S.H., Burns T.F., Ajuha H., Page R., Wu G.S., Chen Y., McKenna W.G., Bernhard E., Lowe S., Mak T., and El-Deiry W.S. DR5 Knockout mice are compromised in radiation-induced apoptosis. Mol. Cell. Biol. 25 (2005) 2000-2013
29. Pan G.H., Bauer J.H., Haridas V., Wang S., Liu D., Yu G., Vincenz C., Aggarwal B.B., Ni J., and Dixit V.M. Identification and functional characterization of DR6, a novel death domain-containing TNF receptor. FEBS Lett. 431 (1998) 351-356
30. Zhao H., Yan M., Wang H., Erickson S., Grewal I.S., and Dixit V.M. Impaired c-Jun amino terminal kinase activity and T-cell differentiation in death receptor 6-deficient mice. J. Exp. Med. 194 (2001) 1441-1448
31. Mikkola M.L., and Thesleff I. Ectodysplasin signaling in development. Cytokine Growth Factor Rev. 14 (2003) 211-224
32. Pispa J., and Thesleff I. Mechanisms of ectodermal organogenesis. Dev. Biol. 262 (2003) 195-205
33. Ezer S., Bayés M., Elomaa O., Schlessinger D., and Kere J. Ectodysplasin is a collagenous trimeric type II membrane protein with a tumor necrosis factor-like domain and co-localizes with cytoskeletal structures at lateral and apical surfaces of cells. Hum. Mol. Genet. 8 (1999) 2079-2086
34. Chen Y., Molloy S.S., Thomas L., Gambee J., Bächinger H.P., Ferguson B., Zonana J., Thomas G., and Morris N.P. Mutations within a furin consensus sequence block proteolytic release of ectodysplasin-A and cause X-linked hypohidrotic ectodermal dysplasia. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 7218-7223
35. Elomaa O., Pulkkinen K., Hannelius U., Mikkola M., Saarialho-Kere U., and Kere J. Ectodysplasin is released by proteolytic shedding and binds to the EDAR protein. Hum. Mol. Genet. 10 (2001) 953-962
36. Bayes M., Hartung A.J., Ezer S., Pispa J., Thesleff I., Srivastava A.K., and Kere J. The anhidrotic ectodermal dysplasia gene (EDA) undergoes alternative splicing and encodes ectodysplasin-A with deletion mutations in collagenous repeats. Hum. Mol. Genet. 7 (1998) 1661-1669
37. Yan M., Wang L.C., Hymowitz S.G., Schilbach S., Lee J., Goddard A., de Vos A.M., Gao W.Q., and Dixit V.M. Two-amino acid molecular switch in an epithelial morphogen that regulates binding to two distinct receptors. Science 290 (2000) 523-527
38. Doffinger R., Smahi A., Bessia C., Geissmann F., Feinberg J., Durandy A., Bodemer C., Kenwrick S., Dupuis-Girod S., Blanche S., Wood P., Rabia S.H., Headon D.J., Overbeek P.A., Le Deist F., Holland S.M., Belani K., Kumararatne D.S., Fischer A., Shapiro R., Conley M.E., Reimund E., Kalhoff H., Abinun M., Munnich A., Israël A., Courtois G., and Casanova J.L. X-linked anhidrotic ectodermal dysplasia with immunodeficiency is caused by impaired NF-kappa-B signaling. Nat. Genet. 27 (2001) 277-285
39. Sinha S.K., Zachariah S., Quiñones H.I., Shindo M., and Chaudhary P.M. Role of TRAF3 and -6 in the activation of the NF-kappa-B and JNK pathways by X-linked ectodermal dysplasia receptor. J. Biol. Chem. 277 (2002) 44953-44961
40. Mustonen T., Pispa J., Mikkola M.L., Pummila M., Kangas A.T., Pakkasjärvi L., Jaatinen R., and Thesleff I. Stimulation of ectodermal organ development by ectodysplasin-A1. Dev. Biol. 259 (2003) 123-136
41. Mustonen T., Ilmonen M., Pummila M., Kangas A.T., Laurikkala J., Jaatinen R., Pispa J., Gaide O., Schneider P., Thesleff I., and Mikkola M.L. Ectodysplasin A1 promotes placodal cell fate during early morphogenesis of ectodermal appendages. Development 131 (2004) 4907-4919
42. Zhang M., Brancaccio A., Weiner L., Missero C., and Brissette J.L. Ectodysplasin regulates pattern formation in the mammalian hair coat. Genesis 37 (2003) 30-37
43. Barker P.A., and Murphy R.A. The nerve growth factor receptor: a multicomponent system that mediates the actions of the neurotrophin family of proteins. Mol. Cel. Biochem. 110 (1992) 1-15
44. Rodriguez-Tebar A., Dechant G., Götz R., and Barde Y.A. Binding of neurotrophin-3 to its neuronal receptors and interactions with nerve growth factor and brain-derived neurotrophic factor. EMBO J. 11 (1992) 917-922
45. Hempstead B.L., Martin-Zanca D., Kaplan D.R., Parada L.F., and Chao M.V. High-affinity NGF binding requires coexpression of the trk proto-oncogene and the low-affinity NGF receptor. Nature 350 (1991) 678-683
46. Kaplan D.R., Hempstead B.L., Martin-Zanca D., Chao M.V., and Parada L.F. The trk proto-oncogene product: a signal transducing receptor for nerve growth factor. Science 252 (1991) 554-558
47. Peter M.E., and Krammer P.H. The CD95 (APO-1/Fas) DISC and beyond. Cell Death Differ. 10 (2003) 26-35
48. Lavrik I., Golks A., and Krammer P.H. Death receptor signaling. J. Cell Sci. 118 (2005) 265-267
49. Sprick M., Rieser E., Stahl H., Grosse-Wilde A., Weigand M., and Walczak H. Caspase-10 is recruited to and activated at the native TRAIL and CD95 death-inducing signaling complexes in FADD-dependent manner but can not functionally substitute caspase-8. EMBO J. 21 (2002) 4520-4530
50. Chang D.W., Xing Z., Capacio V.L., Peter M.E., and yang X. Interdimer processing mechanism of procaspase-8 activation. EMBO J. 22 (2003) 4132-4142
51. Micheau O., and Tschopp J. Induction of TNF receptor I-mediated apoptosis via two sequential signaling complexes. Cell 114 (2003) 181-190
52. Thome M., Schneider P., Hofmann K., Fickenscher H., Meinl E., Neipel F., Mattmann C., Burns K., Bodmer J.-L., Schröter M., Scaffidl C., Krammer P.H., Peter M.E., and Tschopp J. Viral FLICE-inhibitory proteins (FLIPs) prevent apoptosis induced by death receptors. Nature 386 (1997) 517-521
53. Scaffidi C., Fulda S., Srinivasan A., Friesen C., Li F., Tomaselli K.J., Debatin K.M., Krammer P.H., and Peter M.E. Two CD95 (APO-1/Fas) signaling pathways. EMBO J. 17 (1998) 1675-1687
54. Willis S., Day C.L., Hinds M.G., and Huang D.C. The Bcl-2 regulated apoptotic pathway. J. Cell. Sci. 116 (2003) 4053-4056
55. Weil R., and Israël A. T-cell-receptor- and B-cell-receptor-mediated activation of NF-kappaB in lymphocytes. Curr. Opin. Immunol. 3 (2004) 374-381
56. Wang C.Y., Mayo M.W., Korneluk R.G., Goeddell D.V., and Baldwin A.S. NF-κB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and IAP2 to suppress caspase 8 activation. Science 281 (1998) 1680-1683
57. Kataoka T., Budd R.C., Holler N., Thome M., Martinon F., Irmler M., Burns K., Hahne M., Kennedy N., Kovacsovics M., and Tschopp J. The caspase-8 inhibitor FLIP promotes activation of NF-kappaB and Erk signaling pathways. Curr. Biol. 11 (2000) 640-648
58. Budd R.C. Death receptors couple to both cell proliferation and apoptosis. J. Clin. Invest. 4 (2002) 437-442
59. Dyer M.J., MacFarlane M., and Cohen G.M. Barriers to effective TRAIL-targeted therapy of malignancy. J. Clin. Oncol. 25 (2007) 4505-4506
60. Mahalingam D., Szegezdi E., Keane M., Jong S., and Samali A. TRAIL receptor signaling and modulation: Are we on the right TRAIL?. Cancer Treat. Rev. 3 (2009) 280-288
61. Yonehara S., Ishii A., and Yonehara M. A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen co-down-regulated with the receptor of tumor necrosis factor. J. Exp. Med. 169 (1989) 1747-1756
62. Fulda S., Kufer M.U., Meyer E., van Valen F., Dockhorn-Dworniczak B., and Debatin K.M. Sensitization for death receptor- or drug induced apoptosis by re-expression of caspase-8 through demethylation or gene transfer. Oncogene 20 (2001) 5865-5877
63. Houghton J.A., Harwood F.G., and Tillman D.M. Thymineless death in colon carcinoma cells is mediated via-Fas-signaling. Proc. Natl. Acad. Sci. U. S. A. 94 (1997) 8144-8149
64. Kasibhatla S., Brunner T., Genestier L., Echeverri F., Mahboubi A., and Green D.R. DNA damaging agents induce expression of Fas ligand and subsequent apoptosis in T lymphocytes via the activation of NF-kappa B and AP-1. Mol. Cell 1 (1998) 543-551
65. Muller M., Wilder S., Bannasch D., Israeli D., Lehlbach K., Li-Weber M., Friedman S.L., Galle P.R., Stremmel W., Oren M., and Krammer P.H. p53 Activates the CD95 (APO-1/Fas) gene in response to DNA damage by anticancer drugs. J. Exp. Med. 188 (1998) 2033-2045
66. Micheau O., Hammann A., Solary E., and Dimanche-boitrel M.T. Stat-1-independent up-regulation of FADD and procaspase-3 and -8 in cancer cells treated with cytotoxic drugs. Biochem. Biophys. Res. Commun. 256 (1999) 603-607
67. Fulda S., Meyer E., Friesen C., Susin S.A., Kroemer G., and Debatin K.M. Cell type specific involvement of death receptor and mitochondrial pathways in drug-induced apoptosis. Oncogene 20 (2001) 1063-1075
68. Lassus P., Opitz-Araya X., and Lazebnik Y. Requirement for caspase-2 in stress-induced apoptosis before mitochondrial permeabilization. Science 297 (2002) 1352-1354
69. Marsden V.S., O'Connor L., O'Reilly L.A., Silke J., Metcalf D., Ekert P.G., Huang D.C., Cecconi F., Kuida K., Tomaselli K.J., Roy S., Nicholson D.W., Vaux D.L., Bouillet P., Adams J.M., and Strasser A. Apoptosis initiated by Bcl-2-regulated caspase activation independently of the cytochrome c/Apaf-1/caspase-9 apoptosome. Nature 419 (2002) 634-637
70. Arai H., Gordon D., Nabel E.G., and Nabel G.J. Gene transfer of Fas ligand induces tumor regression in vivo. Proc. Natl. Acad. Sci. U. S. A. 94 (1997) 13862-13867
71. Hedlund T.E., Meech S.J., Srikant S., Kratt A.S., Miller G.J., Schaack J.B., and Duke R.C. Adenovirus-mediated expression of Fas ligand induces apoptosis of human prostrate cancer cells. Cell Death Differ. 6 (1999) 175-182
72. Lawrence D., Shahrokh Z., Marsters S., Achilles K., Shih D., Mounho B., Hillan, Totpal K., DeForge L., Schow P., Hooley J., Sherwood S., Pai R., Leung S., Khan L., Gliniak B., Bussiere J., Smith C.A., Strom S.S., Kelley S., Fox J.A., Thomas D., and Ashkenazi A. Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions. Nat. Med. 4 (2001) 383-385
73. Jo M., Kim T.H., Seol D.W., Esplen J.E., Dorko K., Billiar T.R., and Strom S.C. Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand. Nat. Med. 6 (2000) 564-567
74. Nagane M., Huang H.J., and Canvenee W.K. The potential of TRAIL for cancer chemotherapy. Apoptosis 6 (2001) 191-197
75. Bellail A.C., Qi L., Mulligan P., Chhabra V., and Hao C. TRAIL agonists on clinical trials for cancer therapy: the promises and the challenges. Rev. Recent Clin. Trials 1 (2009) 34-41
76. Maduro J.H., Noordhuis M.G., ten Hoor K.A., Pras E., Arts H.J., Eijsink J.J., Hollema H., Mom C.H., de Jong S., de Vries E.G., de Bock G.H., and van der Zee A.G. The prognostic value of TRAIL and its death receptors in cervical cancer. Int. J. Radiat. Oncol. Biol. Phys. 1 (2009) 203-211
77. Hernandez A., Thomas R., Smith F., Sandberg J., Kim S., Chung D.H., and Evers B.M. Butyrate sensitizes human colon cancer cells to TRAIL-mediated apoptosis. Surgery 130 (2001) 265-272
78. Lee Y.J., Lee K.H., Kim H.R., Jessup J.M., Seol D.W., Kim T.H., Billiar T.R., and Song Y.K. Sodium nitroprusside enhances TRAIL-induced apoptosis via a mitochondria dependent pathway in human colorectal carcinoma CX-1 cells. Oncogene 20 (2001) 1476-1485
79. Hernandez A., Wang Q.D., Schwartz S.A., and Evers B.M. Sensitization of human colon cancer cells to TRAIL-mediated apoptosis. J. Gastrointest. Surg. 5 (2001) 56-65
80. Lacour S., Hammann A., Wotawa A., Corcos L., Solary E., and Dimanche-Boitrel M.T. Anticancer agents sensitize tumor cells to tumor necrosis factor-related apoptosis-inducing ligand-mediated caspase-8 activation and apoptosis. Cancer Res. 61 (2001) 1645-1651
81. Gliniak B., and Le T. Tumor necrosis factor-related apoptosis-inducing ligand's antitumor activity in vivo is enhanced by the chemotherapeutic agent CPT-11. Cancer Res. 59 (1999) 6153-6158
82. Gardnerova M., Blanque R., and Gardner C.R. The use of TNF family ligands and receptors and agents which modify their interaction as therapeutic agents. Curr. Drug Targets 1 (2000) 327-364
83. Mitsiades N., Mitsiades C.S., Poulaki V., Chauhan D., Richardson P.G., Hideshima T., Munshi N., Treon S.P., and Anderson K.C. Biologic sequelae of nuclear factor-kappaB blockade in multiple myeloma: therapeutic applications. Blood 99 (2002) 4079-4086
84. Jazirehi A.R., Ng C.P., Gan X.H., Schiller G., and Bonavida B. Adriamycin sensitizes the adriamycin-resistant 8226/Dox40 human multiple myeloma cells to Apo2L/tumor necrosis factor-related apoptosis-inducing ligand-mediated (TRAIL) apoptosis. Clin. Cancer Res. 7 (2001) 3874-3883
85. Rohn T.A., Wagenknecht B., Roth W., Naumann U., Gulbins E., Krammer P.H., Walczak H., and Weller M. CCNU-dependent potentiation of TRAIL/Apo2L-induced apoptosis in human glioma cells is p53-independent but may involve enhanced cytochrome c release. Oncogene 20 (2001) 4128-4137
86. Nagane M., Pan G., Weddle J.J., Dixit V.M., Cavenee W.K., and Huang H.J. Increased death receptor 5 expression by chemotherapeutic agents in human gliomas causes synergistic cytotoxicity with tumor necrosis factor-related apoptosis-inducing ligand in vitro and in vivo. Cancer Res. 60 (2000) 847-853
87. Cuello M., Ettenberg S.A., Clark A.S., Keane M.M., Posner R.H., Nau M.M., Dennis P.A., and Lipkowitz S. Down-regulation of the erbB-2 receptor by trastuzumab (herceptin) enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in breast and ovarian cancer cell lines that overexpress erbB-2. Cancer Res. 61 (2001) 4892-4900
88. Vignati S., Codegoni A., Polato F., and Broggini M. TRAIL activity in human ovarian cancer cells: Potentiation of the action of cytotoxic drugs. Eur. J. Cancer 38 (2002) 177-183
89. Cuello M., Ettenberg S.A., Nau M.M., and Lipkowitz S. Synergistic induction of apoptosis by the combination of trail and chemotherapy in chemoresistant ovarian cancer cells. Gynecol. Oncol. 81 (2001) 380-390
90. Keane M.M., Ettenberg S.A., Nau M.M., Russell E.K., and Lipkowitz S. Chemotherapy augments TRAIL-induced apoptosis in breast cell lines. Cancer Res. 59 (1999) 734-741
91. Chinnaiyan A.M., Prasad U., Shankar S., Hamstra D.A., Shanaiah M., Chenevert T.L., Ross B.D., and Rehemtulla A. Combined effect of tumor necrosis factor-related apoptosis-inducing ligand and ionizing radiation in breast cancer therapy. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 1754-1759
92. Naka T., Sugamura K., Hylander B.L., Widmer M.B., Rustum Y.M., and Repasky E.A. Effects of tumor necrosis factor-related apoptosis-inducing ligand alone and in combination with chemotherapeutic agents on patients' colon tumors grown in SCID mice. Cancer Res. 62 (2002) 5800-5806
93. Hylander B.L., Pitoniak R., Penetrante R.B., Gibbs J.F., Oktay D., Cheng J., and Repasky E.A. The anti-tumor effect of Apo2L/TRAIL on patient pancreatic adenocarcinomas grown as xenografts in SCID mice. J. Transl. Med. 3 (2005) 22
94. Belka C., Schmid B., Marini P., Durand E., Rudner J., Faltin H., Bamberg M., Schulze-Osthoff K., and Budach W. Sensitization of resistant lymphoma cells to irradiation-induced apoptosis by the death ligand TRAIL. Oncogene 20 (2001) 2190-2196
95. Gong B., and Almasan A. Apo2 ligand/TNF-related apoptosis-inducing ligand and death receptor 5 mediate the apoptotic signaling induced by ionizing radiation in leukemic cells. Cancer Res. 60 (2000) 5754-5760
96. Eggert A., Grotzer M.A., Zuzak T.J., Wiewrodt B.R., Ho R., Ikegaki N., and Brodeur G.M. Resistance to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in neuroblastoma cells correlates with a loss of caspase-8 expression. Cancer Res. 61 (2001) 1314-1319
97. Grotzer M.A., Eggert A., Zuzak T.J., Janss A.J., Marwaha S., Wiewrodt B.R., Ikegaki N., Brodeur G.M., and Phillips P.C. Resistance to TRAIL-induced apoptosis in primitive neuroectodermal brain tumor cells correlates with a loss of caspase-8 expression. Oncogene 19 (2000) 4604-4610
98. Matsuzaki H., Schmied B.M., Ulrich A., Standop J., Schneider M.B., Batra S.K., Picha K.S., and Pour P.M. Combination of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and actinomycin D induces apoptosis even in TRAIL-resistant human pancreatic cancer cells. Clin. Cancer Res. 7 (2001) 407-414
99. Nimmanapalli R., Porosnicu M., Nguyen D., Worthington E., O'Bryan E., Perkins C., and Bhalla K. Cotreatment with STI-571 enhances tumor necrosis factor alpha-related apoptosis-inducing ligand (TRAIL or apo-2L)-induced apoptosis of Bcr-Abl-positive human acute leukemia cells. Clin. Cancer Res. 7 (2001) 350-357
100. Di Pietro R., Secchiero P., Rana R., Gibellini D., Visani G., Bemis K., Zamai L., Miscia S., and Zauli G. Ionizing radiation sensitizes erythroleukemic cells but not normal erythroblasts to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated cytotoxicity by selective up-regulation of TRAIL-R1. Blood 97 (2001) 2596-2603
101. Olsson A., Diaz T., Aguilar-Santelises M., Osterborg A., Celsing F., Jondal M., and Osorio L.M. Sensitization to TRAIL-induced apoptosis and modulation of FLICE-inhibitory protein in B chronic lymphocytic leukemia by actinomycin D. Leukemia 15 (2001) 1868-1877
102. Inoue S., MacFarlane M., Harper N., Wheat L.M., Dyer M.J., and Cohen G.M. Histone deacetylase inhibitors potentiate TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in lymphoid malignancies. Cell Death Differ. 11 (2004) S193-S206
103. MacFarlane M., Inoue S., Kohlhaas S.L., Majid A., Harper N., Kennedy D.B., Dyer M.J., and Cohen G.M. Chronic lymphocytic leukemic cells exhibit apoptotic signaling via TRAILR1. Cell Death Differ 12 (2005) 773-782
104. Wuchter C., Krappmann D., Cai Z., Ruppert V., Scheidereit C., Dörken B., Ludwig W.D., and Karawajew L. In vitro susceptibility to TRAIL-induced apoptosis of acute leukemia cells in the context of TRAIL receptor gene expression and constitutive NF-kappa B activity. Leukemia 15 (2001) 921-928
105. Leverkus M., Neumann M., Mengling T., Rauch C.T., Bröcker E.B., Krammer P.H., and Walczak H. Regulation of tumor necrosis factor-related apoptosis-inducing ligand sensitivity in primary and transformed human keratinocytes. Cancer Res. 60 (2000) 553-559
106. Nimmanapalli R., Perkins C.L., Orlando M., O'Bryan E., Nguyen D., and Bhalla K.N. Pretreatment with paclitaxel enhances apo-2 ligand/tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of prostate cancer cells by inducing death receptors 4 and 5 protein levels. Cancer Res. 61 (2001) 759-763
107. Voelkel-Johnson C., King D.L., and Norris J.S. Resistance of prostate cancer cells to soluble TNF-related apoptosis-inducing ligand (TRAIL/Apo2L) can be overcome by doxorubicin or adenoviral delivery of full-length TRAIL. Cancer Gene Ther. 9 (2002) 164-172
108. Schneider P., and Tschopp J. Apoptosis induced by death receptors. Pharm. Acta. Helv. 74 (2000) 281-286
109. Mizutani Y., Nakanishi H., Yoshida O., Fukushima M., Bonavida B., and Miki T. Potentiation of the sensitivity of renal cell carcinoma cells to TRAIL-mediated apoptosis by subtoxic concentrations of 5-fluorouracil. Eur. J. Cancer 38 (2002) 167-176
110. Mizutani Y., Nakao M., Ogawa O., Yoshida O., Bonavida B., and Miki T. Enhanced sensitivity of bladder cancer cells to tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis by cisplatin and carboplatin. J. Urol. 165 (2001) 263-270
111. Yamanaka T., Shiraki K., Sugimoto K., Ito T., Fujikawa K., Ito M., Takase K., Moriyama M., Nakano T., and Suzuki A. Chemotherapeutic agents augment TRAIL-induced apoptosis in human hepatocellular carcinoma cell lines. Hepatology 32 (2000) 482-490
112. Van Valen F., Fulda S., Truckenbrod B., Eckervogt V., Sonnemann J., Hillmann A., Rödl R., Hoffmann C., Winkelmann W., Schäfer L., Dockhorn-Dworniczak B., Wessel T., Boos J., Debatin K.M., and Jürgens H. Apoptotic responsiveness of the Ewing's sarcoma family of tumours to tumour necrosis factor-related apoptosis-inducing ligand (TRAIL). Int. J. Cancer 88 (2000) 252-259
113. Nebbioso A., Clarke N., Voltz E., Germain E., Ambrosino C., Bontempo P., Alvarez R., Schiavone E.M., Ferrara F., Bresciani F., Weisz A., de Lera A.R., Gronemeyer H., and Altucci L. Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells. Nat. Med. 11 (2005) 77-84